Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2020-10-08 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于子公司股权转让暨募投项目转让的补充公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding a subsidiary equity transfer and related fundraising project transfer. It includes details about the transaction counterparties, repayment arrangements for a loan by a subsidiary, and risk warnings. The document is an announcement of a corporate transaction and related risks, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive information about the transaction itself. The content fits best under Capital/Financing Update (CAP) as it relates to equity transfer and financing arrangements.
2020-10-08 Chinese
上海荣正投资咨询股份有限公司关于昆药集团股份有限公司2017年限制性股票激励计划回购注销部分限制性股票事项之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is an Independent Financial Advisor Report related to the repurchase and cancellation of restricted shares under the 2017 restricted stock incentive plan of Kunming Pharmaceutical Group Co., Ltd. It contains detailed explanations, approvals, and opinions on the repurchase and cancellation of restricted stock, including legal and regulatory compliance references. The document is not a full annual or interim financial report, nor is it a brief announcement or a certification. It is a standalone advisory report focused on a specific capital/financing activity (repurchase and cancellation of restricted shares). Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (5908 characters) and content support this classification with high confidence.
2020-09-29 Chinese
东海证券股份有限公司关于昆药集团股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Donghai Securities regarding Kunming Pharmaceutical Group Co., Ltd.'s use of temporarily idle raised funds for cash management. It references regulatory approvals, fundraising details, investment projects, and compliance with relevant securities regulations. The document is not a full financial report but rather an audit or verification opinion related to the use of raised funds. It includes detailed investigation and confirmation of proper procedures and risk controls, typical of an audit or verification report. The document length is 4124 characters, which is relatively short but contains substantive content beyond a mere announcement. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It is not a simple announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). The content fits best with an Audit Report / Information (AR) category, as it involves an audit institution's opinion on the use of funds and compliance with regulations. FY 2020
2020-09-29 Chinese
关于利用闲置自有资金进行投资理财业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the use of idle funds for investment in financial products. It details the board and supervisory committee's approval, investment purpose, authorization limits, risk control measures, and the need for shareholder approval. The document is a formal public announcement about a financing-related decision but does not contain financial statements or detailed financial results. It is not a full financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it relates to the company's financing activities and capital management decisions.
2020-09-29 Chinese
独立董事关于公司九届三十二次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including use of idle raised funds, stock repurchase and cancellation related to an incentive plan, subsidiary equity transfer, and related party transactions. It references compliance with laws and regulations and confirms the legality and fairness of the board's decisions. The content is focused on board-level approvals and independent director opinions rather than financial results, audit opinions, or shareholder voting results. It is not a full annual or interim report, nor a voting result announcement. The document fits best as Board/Management Information (MANG) because it concerns board meeting matters and independent directors' opinions on corporate governance and management decisions.
2020-09-29 Chinese
关于公司参股南京维立志博生物科技有限公司暨与关联人形成共同投资关系的关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a related-party transaction involving Kunming Pharmaceutical Group Co., Ltd. It discusses the company's investment in Nanjing Weilizhibo Biotechnology Co., Ltd., including the background, financial details, investment terms, risk factors, and approval procedures. The document includes specifics about the transaction, the parties involved, and the strategic significance of the investment. It is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not a call transcript, earnings release, or legal proceeding update. The content fits the category of a Capital/Financing Update (CAP) because it details a financing-related transaction (investment and related-party transaction) and its terms. The document length and detail support this classification with high confidence.
2020-09-29 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.